Compare Stocks: TECX, NUVB, BHVN, and PHVS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHVN Biohaven	$15.90 +1.3%	$14.86	$7.48 ▼ $18.57	$2.37B	1.28	3.03 million shs	2.26 million shs
NUVB Nuvation Bio	$6.73 -2.9%	$6.32	$2.99 ▼ $9.75	$2.43B	1.52	5.50 million shs	5.27 million shs
PHVS Pharvaris	$35.66 +1.4%	$34.76	$20.65 ▼ $38.13	$2.30B	-2.33	673,549 shs	356,947 shs
TECX Tectonic Therapeutic	$29.92 -1.5%	$33.14	$14.39 ▼ $39.53	$593.91M	3.31	247,563 shs	140,381 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHVN Biohaven	+0.76%	-1.14%	+15.78%	+46.64%	-1.91%
NUVB Nuvation Bio	-2.82%	-3.79%	+4.26%	+39.77%	+113.24%
PHVS Pharvaris	+1.39%	-3.62%	+5.28%	+14.70%	+62.76%
TECX Tectonic Therapeutic	-1.51%	-18.47%	+2.57%	+3.17%	+83.22%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHVN Biohaven	$15.90 +1.3%	$14.86	$7.48 ▼ $18.57	$2.37B	1.28	3.03 million shs	2.26 million shs
NUVB Nuvation Bio	$6.73 -2.9%	$6.32	$2.99 ▼ $9.75	$2.43B	1.52	5.50 million shs	5.27 million shs
PHVS Pharvaris	$35.66 +1.4%	$34.76	$20.65 ▼ $38.13	$2.30B	-2.33	673,549 shs	356,947 shs
TECX Tectonic Therapeutic	$29.92 -1.5%	$33.14	$14.39 ▼ $39.53	$593.91M	3.31	247,563 shs	140,381 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHVN Biohaven	+0.76%	-1.14%	+15.78%	+46.64%	-1.91%
NUVB Nuvation Bio	-2.82%	-3.79%	+4.26%	+39.77%	+113.24%
PHVS Pharvaris	+1.39%	-3.62%	+5.28%	+14.70%	+62.76%
TECX Tectonic Therapeutic	-1.51%	-18.47%	+2.57%	+3.17%	+83.22%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHVN Biohaven	2.65	Moderate Buy	$18.94	19.10% Upside
NUVB Nuvation Bio	2.69	Moderate Buy	$13.00	93.16% Upside
PHVS Pharvaris	2.86	Moderate Buy	$51.08	43.23% Upside
TECX Tectonic Therapeutic	2.88	Moderate Buy	$77.25	158.19% Upside

Current Analyst Ratings Breakdown

Latest TECX, NUVB, BHVN, and PHVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	TECX Tectonic Therapeutic	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/28/2026	BHVN Biohaven	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/28/2026	BHVN Biohaven	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$21.00
8/27/2026	BHVN Biohaven	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/26/2026	BHVN Biohaven	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/26/2026	BHVN Biohaven	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$30.00
8/21/2026	NUVB Nuvation Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight
8/18/2026	NUVB Nuvation Bio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$13.00
8/18/2026	TECX Tectonic Therapeutic	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/14/2026	PHVS Pharvaris	New Street Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$60.00
8/14/2026	PHVS Pharvaris	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHVN Biohaven	N/A	N/A	N/A	N/A	$0.08 per share	N/A
NUVB Nuvation Bio	$62.90M	37.57	N/A	N/A	$0.72 per share	9.35
PHVS Pharvaris	N/A	N/A	N/A	N/A	$5.35 per share	N/A
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	$11.45 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHVN Biohaven	-$738.82M	-$4.64	N/A	N/A	N/A	N/A	-1,328.94%	-138.27%	11/9/2026 (Estimated)
NUVB Nuvation Bio	-$204.63M	-$0.44	N/A	N/A	N/A	-88.18%	-46.59%	-22.01%	11/2/2026 (Estimated)
PHVS Pharvaris	-$198.79M	-$3.05	N/A	N/A	N/A	N/A	-61.40%	-56.00%	11/11/2026 (Estimated)
TECX Tectonic Therapeutic	-$74.15M	-$4.57	N/A	N/A	N/A	N/A	-35.26%	-33.59%	11/5/2026 (Estimated)

Latest TECX, NUVB, BHVN, and PHVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	PHVS Pharvaris	-$0.7467	-$0.81	-$0.0633	-$0.80	N/A	N/A
8/10/2026	Q2 2026	BHVN Biohaven	-$0.7610	-$0.91	-$0.1490	-$0.91	$0.49 million	N/A
8/6/2026	Q2 2026	NUVB Nuvation Bio	-$0.1417	-$0.15	-$0.0083	-$0.18	$27.03 million	$31.69 million
8/6/2026	Q2 2026	TECX Tectonic Therapeutic	-$1.35	-$1.18	+$0.17	-$1.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHVN Biohaven	21.23	4.73	4.73
NUVB Nuvation Bio	0.96	8.37	8.14
PHVS Pharvaris	N/A	11.94	11.94
TECX Tectonic Therapeutic	N/A	22.29	22.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHVN Biohaven	88.78%
NUVB Nuvation Bio	61.67%
PHVS Pharvaris	N/A
TECX Tectonic Therapeutic	62.63%

Insider Ownership

Company	Insider Ownership
BHVN Biohaven	13.80%
NUVB Nuvation Bio	30.11%
PHVS Pharvaris	11.84%
TECX Tectonic Therapeutic	39.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHVN Biohaven	239	151.04 million	130.20 million	Optionable
NUVB Nuvation Bio	60	351.12 million	245.40 million	Optionable
PHVS Pharvaris	30	65.41 million	57.66 million	Not Optionable
TECX Tectonic Therapeutic	120	19.55 million	11.77 million	N/A

TECX, NUVB, BHVN, and PHVS Headlines

Recent News About These Companies

Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference

September 3 at 8:00 AM | globenewswire.com

Braidwell LP Cuts Stake in Tectonic Therapeutic, Inc. $TECX

September 3 at 4:23 AM | marketbeat.com

BlackRock Inc. Makes New Investment in Tectonic Therapeutic, Inc. $TECX

September 2 at 3:35 AM | marketbeat.com

Tectonic Therapeutic: Competitor Data Strengthens The TX45 Bull Case

September 2 at 2:00 AM | seekingalpha.com

Tectonic Therapeutic (NASDAQ:TECX) Shares Up 5.4% - What's Next?

September 1 at 3:39 PM | marketbeat.com

Tectonic Therapeutic, Inc. (NASDAQ:TECX) Given Average Recommendation of "Moderate Buy" by Brokerages

September 1 at 4:13 AM | marketbeat.com

Tectonic Therapeutic (NASDAQ:TECX) Shares Down 8.4% - What's Next?

August 31, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Invests $2.23 Million in Tectonic Therapeutic, Inc. $TECX

August 30, 2026 | marketbeat.com

606,660 Shares in Tectonic Therapeutic, Inc. $TECX Purchased by 5AM Venture Management LLC

August 26, 2026 | marketbeat.com

Tectonic Therapeutic (NASDAQ:TECX) Upgraded to "Hold" at Zacks Research

August 20, 2026 | marketbeat.com

Tectonic Therapeutic (NASDAQ:TECX) Trading 5.6% Higher - Should You Buy?

August 18, 2026 | marketbeat.com

Stifel Nicolaus Reaffirms Their Buy Rating on Tectonic Therapeutic (TECX)

August 13, 2026 | theglobeandmail.com

Tectonic Therapeutic (NASDAQ:TECX) Trading Up 13.3% - Here's What Happened

August 12, 2026 | marketbeat.com

Tectonic Therapeutic (NASDAQ:TECX) Upgraded by Wall Street Zen to "Sell" Rating

August 8, 2026 | marketbeat.com

Analysts Conflicted on These Healthcare Names: Ginkgo Bioworks Holdings (DNA), InflaRx (IFRX) and Tectonic Therapeutic (TECX)

August 7, 2026 | theglobeandmail.com

Tectonic Therapeutic (NASDAQ:TECX) Announces Earnings Results, Beats Estimates By $0.17 EPS

August 7, 2026 | marketbeat.com

Wells Fargo & Company Issues Pessimistic Forecast for Tectonic Therapeutic (NASDAQ:TECX) Stock Price

August 7, 2026 | marketbeat.com

Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Consensus Rating of "Moderate Buy" from Brokerages

August 7, 2026 | marketbeat.com

Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights

August 6, 2026 | finance.yahoo.com

Tectonic Therapeutic Inc

July 2, 2026 | edition.cnn.com

Why Tectonic Therapeutic, Inc.’s (TECX) Stock Is Up 5.05%

June 30, 2026 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECX, NUVB, BHVN, and PHVS Company Descriptions

Biohaven NYSE:BHVN

$15.90 +0.21 (+1.34%)

Closing price 09/3/2026 03:58 PM Eastern

Extended Trading

$16.18 +0.28 (+1.75%)

As of 04:22 AM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Nuvation Bio NYSE:NUVB

$6.73 -0.20 (-2.89%)

Closing price 09/3/2026 03:58 PM Eastern

Extended Trading

$6.78 +0.05 (+0.82%)

As of 04:00 AM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Pharvaris NASDAQ:PHVS

$35.66 +0.49 (+1.39%)

As of 09/3/2026 04:00 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Tectonic Therapeutic NASDAQ:TECX

$29.92 -0.46 (-1.51%)

As of 09/3/2026 04:00 PM Eastern

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TECX, NUVB, BHVN, and PHVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TECX, NUVB, BHVN, and PHVS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TECX, NUVB, BHVN, and PHVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECX, NUVB, BHVN, and PHVS Company Descriptions

Biohaven NYSE:BHVN

Nuvation Bio NYSE:NUVB

Pharvaris NASDAQ:PHVS

Tectonic Therapeutic NASDAQ:TECX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TECX, NUVB, BHVN, and PHVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TECX, NUVB, BHVN, and PHVS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TECX, NUVB, BHVN, and PHVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECX, NUVB, BHVN, and PHVS Company Descriptions

Biohaven NYSE:BHVN

Nuvation Bio NYSE:NUVB

Pharvaris NASDAQ:PHVS

Tectonic Therapeutic NASDAQ:TECX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools